Qelbree® (viloxazine extended-release capsules)

Qelbree® (viloxazine extended-release capsules) email format

Verified email-pattern data for Qelbree® (Viloxazine Extended-Release Capsules) is currently limited. You can still use the company insights and contact sections below.
Please see full Prescribing Info, including Boxed Warning, at https://bit.ly/4lGkM5r. Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 years and older. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS. In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors. Please see full Important Safety Information in Posts tab above. This page is for healthcare professionals in the US only. Qelbree® is a registered trademark of Supernus Pharmaceuticals, Inc. All other trademarks are the property of their respective owners. ©2024 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2024-0003 This information is intended for use in the United States and Puerto Rico only.
Looking for a particular Qelbree® (viloxazine extended-release capsules) employee's phone or email?

Qelbree® (Viloxazine Extended-Release Capsules) Questions

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant